220 related articles for article (PubMed ID: 35957899)
21. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
Fenerty KE; Padget M; Wolfson B; Gameiro SR; Su Z; Lee JH; Rabizadeh S; Soon-Shiong P; Hodge JW
J Immunother Cancer; 2018 Nov; 6(1):133. PubMed ID: 30486888
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
24. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
25. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
26. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
27. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
Serra-Camprubí Q; Verdaguer H; Oliveros W; Lupión-Garcia N; Llop-Guevara A; Molina C; Vila-Casadesús M; Turpin A; Neuzillet C; Frigola J; Querol J; Yáñez-Bartolomé M; Castet F; Fabregat-Franco C; Escudero-Iriarte C; Escorihuela M; Arenas EJ; Bernadó-Morales C; Haro N; Giles FJ; Pozo ÓJ; Miquel JM; Nuciforo PG; Vivancos A; Melé M; Serra V; Arribas J; Tabernero J; Peiró S; Macarulla T; Tian TV
Clin Cancer Res; 2023 Jan; 29(2):432-445. PubMed ID: 36374558
[TBL] [Abstract][Full Text] [Related]
28. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
[TBL] [Abstract][Full Text] [Related]
29. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Fehling SC; Miller AL; Garcia PL; Vance RB; Yoon KJ
Cancer Lett; 2020 Jan; 468():48-58. PubMed ID: 31605774
[TBL] [Abstract][Full Text] [Related]
30. Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a
Li W; Ma Z; Fu X; Hao Z; Shang H; Shi J; Lei M; Xu M; Ning S; Hua X
Ann Transl Med; 2021 Sep; 9(18):1487. PubMed ID: 34734039
[TBL] [Abstract][Full Text] [Related]
31. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
33. Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.
Zhao L; Singh V; Ricca A; Lee P
J Med Cases; 2022 May; 13(5):240-243. PubMed ID: 35655630
[TBL] [Abstract][Full Text] [Related]
34. Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature.
Song M; Zeng X; Wu Q; Huang J; Dong J; Shao L; Sun Z; Lin Y; Chen S
Life (Basel); 2023 May; 13(5):. PubMed ID: 37240828
[TBL] [Abstract][Full Text] [Related]
35. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of a
Bredow K; Blümcke B; Schneider S; Püsken M; Schmutzler R; Rhiem K
Mol Clin Oncol; 2022 Sep; 17(3):137. PubMed ID: 35949895
[No Abstract] [Full Text] [Related]
37. Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
Anzellini D; Arcangeli G; Del Bianco S
Cancer Diagn Progn; 2022; 2(1):84-86. PubMed ID: 35400012
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
39. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
